Back to Search Start Over

PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review

PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review

Authors :
Anthony Gonçalves
Philippe Rochigneux
Patrice Viens
Anne-Sophie Chretien
Gabrielle Planes-Laine
François Bertucci
Renaud Sabatier
Centre de Recherche en Cancérologie de Marseille (CRCM)
Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes
Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU)
Institut Paoli-Calmettes
Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)
Aix Marseille Université (AMU)-Institut Paoli-Calmettes
Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Bidaut, Ghislain
Source :
Cancers, Cancers, MDPI, 2019, 11 (7), pp.1033. ⟨10.3390/cancers11071033⟩, Cancers, 2019, 11 (7), pp.1033. ⟨10.3390/cancers11071033⟩, Cancers, Vol 11, Iss 7, p 1033 (2019)
Publication Year :
2019
Publisher :
MDPI AG, 2019.

Abstract

International audience; Recently, the development of immunotherapy through the immune checkpoint blockade led to long-lasting responses in several types of cancers that are refractory to conventional treatments, such as melanoma or non-small cell lung cancer. Immunotherapy has also demonstrated significant improvements in various other types of cancers. However, breast cancer remains one of the tumors that have not experienced the explosion of immunotherapy yet. Indeed, breast cancer was traditionally considered as being weakly immunogenic with a lower mutational load compared to other tumor types. In the last few years, anti-PD1/PD-L1 (Programmed death-ligand 1) agents have been evaluated in breast cancer, particularly in the triple negative subtype, with promising results observed when delivered as monotherapy or in combination with conventional treatments. In this review, we will report the results of the most recent studies evaluating immune checkpoint inhibitors in breast cancer. In addition, we will discuss the concomitant development of possible biomarkers, which is required for improving the selection of patients with the highest probability of benefiting from these agents.

Details

ISSN :
20726694
Volume :
11
Database :
OpenAIRE
Journal :
Cancers
Accession number :
edsair.doi.dedup.....715d0a8b04d79b6ae6f1ac8b0845b958
Full Text :
https://doi.org/10.3390/cancers11071033